Skip to main content

Table 1 Validity of breast cancer flags in individual datasets compared with the Cancer Registry, July 2004-December 2008

From: Ascertaining invasive breast cancer cases; the validity of administrative and self-reported data sources in Australia

Data set Breast cancer flags Positive predictive value Sensitivity Specificity
45 and Up baseline survey1 Self-reported diagnosis of breast cancer 2 within a year of birth-year reported 49.8% 84.7% 99.6%
Admitted Patient Data Collection Diagnosis3 of invasive breast cancer 85.9% 86.1% 99.8%
Lumpectomy 52.0% 60.7% 99.2%
Mastectomy 70.8% 32.6% 99.8%
Lumpectomy OR mastectomy 56.4% 84.4% 99.1%
Lumpectomy AND diagnosis of invasive breast cancer 89.0% 59.1% 99.9%
Mastectomy AND diagnosis of invasive breast cancer 85.4% 31.8% 99.1%
(Lumpectomy or mastectomy) AND diagnosis of invasive breast cancer 87.7% 82.3% 99.8%
(Lumpectomy or mastectomy) OR diagnosis of invasive breast cancer 56.5% 88.2% 99.0%
Mastectomy OR diagnosis of invasive breast cancer 79.7% 87.6% 99.7%
Lumpectomy OR diagnosis of invasive breast cancer 58.2% 87.6% 99.1%
Medicare Benefits Schedule Breast radiotherapy 72.8% 57.6% 99.7%
Pharmaceutical Benefits Scheme Dispensed medicine for breast cancer 4 45.5% 65.4% 98.9%
  1. 1: Comparison to Cancer Registry was restricted to July 2004-December 2005.
  2. 2: Reported cancer with birth-year occurring in or overlapping with the period July 2004-December 2005.
  3. 3: Primary diagnosis field.
  4. 4: Tamoxifen, toremifene, anastrozole, exemestane, letrozole, goserelin, trastuzumab, lapatinib, and medroxyprogesterone 500 mg.